[Safety of proton pump inhibitors].
The significant inhibitory capacity of gastric acid secretion of PPIs makes them the drugs of choice for treating acid-related diseases. The considerable prevalence of these diseases and the need for maintaining the administration of the drug during considerably long periods results in this therapeutic group being one of the most widely used. However, in spite of their extensive use, there continue to emerge concerns about their potential toxicity; concerns surrounding the specificity of their mechanism of action and a consequential suspicion that something so potent must involve harmful effects. PPIs act selectively on the final stage of the process of gastric acid secretion, namely the H+/K+-ATPase or proton pump. This enzyme represents an essential step in the process of secretion of H+, and PPIs exert a very specific action on the parietal cell, as they need an environment with very low pH levels, which only exist in this cell. In the present article, the adverse effects of PPIs are reviewed, with special emphasis on those related to their continued administration and on the special circumstances of patients, as in the case of the elderly, those with liver failure, pregnant and breastfeeding mothers and children. All the PPIs on the market share a common chemical basis and there are no great differences in their potential adverse effects, the possibility of them promoting opportunist infections or their capacity to generate pharmacokinetic interactions with other drugs, which, if occur, are generally insignificant. After two decades of use, PPIs have proved to be very effective and safe drugs.
Esplugues
Juan V
JV
Departamento de Farmacología, Facultat de Medicina i Odontologia, Universitat de Valencia, Valencia, España. juan.v.esplugues@uv.es
Martí-Cabrera
Miguel
M
Ponce
Julio
J
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000009:adverse effects; D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors; D000328:Adult; D000367:Age Factors; D000368:Aged; D000818:Animals; D000897:Anti-Ulcer Agents / Q000009:adverse effects*; D002927:Cimetidine / Q000009:adverse effects; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D015738:Famotidine / Q000009:adverse effects; D005260:Female; D005333:Fetus / Q000187:drug effects; D006635:Histamine H2 Antagonists / Q000009:adverse effects; D006801:Humans; D007774:Lactation; D064747:Lansoprazole; D015201:Meta-Analysis as Topic; D016567:Nizatidine / Q000009:adverse effects; D009853:Omeprazole / Q000009:adverse effects; D000077402:Pantoprazole; D011247:Pregnancy; D054328:Proton Pump Inhibitors; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors; D064750:Rabeprazole; D011899:Ranitidine / Q000009:adverse effects; D012449:Safety; D013997:Time Factors
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D004791:Enzyme Inhibitors; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D064750:Rabeprazole; D015738:Famotidine; D002927:Cimetidine; D011899:Ranitidine; D000077402:Pantoprazole; D000251:Adenosine Triphosphatases; D006180:Proton-Translocating ATPases; D009853:Omeprazole; D016567:Nizatidine